GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI
(natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.
.
( Total: 41 Current Stock Recommendations )
Biogen Idec Inc   (41)
Sell Hold 27% Buy 68%
Related companies
Sanofi-aventis Sa   (17)
Hold 47% Buy 53%
Allergan, Inc.   (30)
Hold 40% Buy 60%
Novo Nordisk A/s   (18)
Sell 17% Hold 44% Buy 39%
Amgen Inc.   (30)
Hold 47% Buy 53%
Gilead Sciences, ...   (48)
Sell Hold 15% Buy 81%
Teva Pharmaceutical ...   (41)
Hold 27% Buy 73%
Celgene Corporation   (44)
Sell Hold Buy 84%
Allergan Plc   (28)
Hold 29% Buy 71%
Filter by Gains:   
  
Rating:
Buy BIIB
up 6.99 %

Rating:
Buy BIIB
up 8.56 %
Biogen Idec Inc (BIIB) rated Outperform by Wells Fargo
Friday,  Dec 4, 2015  10:25 AM ET

Rating:
Buy BIIB
down 3.57 %

Rating:
Hold BIIB
up 35.67 %
Biogen Idec Inc (BIIB) downgraded to Neutral by Piper Jaffray
Wednesday,  Jul 22, 2015  10:25 AM ET

Rating:
Buy BIIB
up 103.19 %

Rating:
Buy BIIB
up 208.12 %

Rating:
Buy BIIB
up 0.09 %

Rating:
Buy BIIB
up 62.38 %
Biogen Idec Inc (BIIB) rated Buy with price target $376 by Stifel
Tuesday,  Aug 19, 2014  12:00 AM ET

Rating:
Buy BIIB
up 62.38 %
Biogen Idec Inc (BIIB) rated Buy with price target $376 by Stifel
Wednesday,  Mar 19, 2014  8:25 AM ET

Rating:
Buy BIIB
up 143.65 %

Rating:
Buy BIIB
up 62.38 %

Rating:
Buy BIIB
up 103.19 %
Biogen Idec Inc (BIIB) rated Buy with price target $360 by Argus
Thursday,  Jan 30, 2014  2:25 PM ET

Rating:
Hold BIIB
Biogen Idec Inc (BIIB) rated Neutral with price target $310 by UBS
Thursday,  Jan 30, 2014  12:25 PM ET

Rating:
Buy BIIB
down 4.33 %

Rating:
Buy BIIB
up 208.12 %

Your Recent Stocks
SymbolLastChange
BIIB 284.59 down  -6.53 %

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy